-transparent.png){kind=logo}
Thalidomide has a beneficial effect on type II Lepra reaction especially chronic and recurrent reaction. It helps to minimise steroid dependency. Thalidomide was given to 94 cases of type II lepra reaction, who had not responded to steroids or had repeated reactions. This clinical data was analysed regarding clinical improvement, relapse of reaction, side effects of the drug, etc. The analysis showed that all the patients improved remarkably and steroids could be withdrawn. If the competence of staff using this drug is enhanced, morbidity due to leprosy can considerably be reduced.
Related Publications
D A Parikh, and
R Ganapati, and
C R Revankar
January 1971,
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
D A Parikh, and
R Ganapati, and
C R Revankar
February 1994,
Lancet (London, England),
D A Parikh, and
R Ganapati, and
C R Revankar
September 1967,
Revista brasileira de medicina,
D A Parikh, and
R Ganapati, and
C R Revankar
August 1985,
Lancet (London, England),
D A Parikh, and
R Ganapati, and
C R Revankar
June 1991,
BMJ (Clinical research ed.),
D A Parikh, and
R Ganapati, and
C R Revankar
November 1991,
BMJ (Clinical research ed.),
D A Parikh, and
R Ganapati, and
C R Revankar
January 1994,
Adverse drug reactions and toxicological reviews,
D A Parikh, and
R Ganapati, and
C R Revankar
August 1991,
BMJ (Clinical research ed.),
D A Parikh, and
R Ganapati, and
C R Revankar
October 1991,
BMJ (Clinical research ed.),
D A Parikh, and
R Ganapati, and
C R Revankar
January 1968,
Bulletin de la Societe francaise de dermatologie et de syphiligraphie,
